Novel pharmacologic therapies in development for acute decompensated heart failure (Q38073647)

28 August 2017

1 reference

title

Novel pharmacologic therapies in development for acute decompensated heart failure (English)

1 reference

acute decompensated heart failure

28 August 2017

main subject

1 reference

Justin A Ezekowitz

1

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Current cardiology reports

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

329

1 reference

Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

End points for clinical trials in acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmia pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Effect of nesiritide in patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

The renal urodilatin system: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Renal effects of ularitide in patients with decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

The vascular actions of relaxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Design of the RELAXin in acute heart failure study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Testosterone therapy in women with heart failure "why can't a woman be more like a man?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

An introduction to acute heart failure syndromes: definition and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-012-0329-Z

Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure

21 January 2018

1 reference

12 December 2020

Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers

1 reference

12 December 2020

N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study

1 reference

12 December 2020

Why do drugs for acute heart failure fail?

1 reference

12 December 2020

Haemodynamic and clinical effects of ularitide in decompensated heart failure

1 reference

12 December 2020

Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated

1 reference

12 December 2020

10.1007/S11886-012-0329-Z

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bqkdok7xuzgidc5hfmfpjeyqrq

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1036248721

0 references

Fatcat ID

release_bqkdok7xuzgidc5hfmfpjeyqrq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bqkdok7xuzgidc5hfmfpjeyqrq

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/bqkdok7xuzgidc5hfmfpjeyqrq

1 reference

30 July 2022